SCHEMBL4101664

SCHEMBL4101664

CCN(CC)CCOc1cc(-c2nc(Cl)nc3c2ncn3Cc2ccc(OC)cc2)c(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
YTHDC1 Q96MU7 6/20 0.47
ADORA2A P29274 1/20 0.42
PDE8A O60658 1/20 0.40
HSP90AB1 P08238 4/20 0.40
HSP90AA1 P07900 2/20 0.40
KCNH2 Q12809 1/20 0.39
CTSL P07711 2/20 0.39
CYP2C19 P33261 1/20 0.38
ESR1 P03372 1/20 0.38
CCNE2 O96020 2/20 0.38
CCNE1 P24864 2/20 0.38
CDK2 P24941 2/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR2 P34972 1/20 0.37
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4101363 0.90 YTHDC1 (0.47) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL4095947 0.84 YTHDC1 (0.46) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL4094742 0.84 YTHDC1 (0.48) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL4096821 0.81 YTHDC1 (0.48) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL4097355 0.81 YTHDC1 (0.42) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL5462820 0.75 ADORA2A (0.54) YTHDC1ADORA2APDE8ACTSLCCNE2
SCHEMBL3821565 0.72 YTHDC1 (0.57) YTHDC1ADORA2APDE8AHSP90AB1HSP90AA1
SCHEMBL4091000 0.71 HSP90AB1 (0.51) HSP90AB1HSP90AA1KCNH2CYP2C19
SCHEMBL21801296 0.71 YTHDC1 (0.56) YTHDC1ADORA2APDE8ACTSLCCNE2
SCHEMBL30496438 0.71 YTHDC1 (0.56) YTHDC1ADORA2APDE8ACTSLCCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer VERNALIS ( R & D) LTD. (GB) 2009-07-16 US disclosed
EP-2004648-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER Vernalis (R&D) Limited (GB) 2008-12-24 EP disclosed
WO-2007034185-A1 PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER VERNALIS (R & D) LTD. (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181989-A1 Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer HSP90AA1, HSP90AB1, HSP90AB2P YTHDC1 1015/4885ADORA2A 1112/4885PDE8A 4309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.